Welcome to N4 Pharma’s educational series, where we take a closer look at the science behind RNA therapeutics and how our Nuvec® gene delivery platform is advancing the field.
In this first video, we introduce N4 Pharma’s strategy—from developing Nuvec® as a next-generation RNA delivery system to building out our pipeline with novel gene therapies. Nuvec® offers unique advantages, including multi-RNA delivery, stability, ease of manufacturing, and protection of the RNA payload. Our lead programme, N4 101, is focused on inflammatory bowel disease (IBD), a market expected to reach $27.6bn by 2030.
Watch now to learn how we are positioning Nuvec® as a potential game-changer in RNA therapeutics—and stay tuned as we explore more in upcoming videos.
